



ALZHEIMER'S RESEARCH *and Treatment Center*

July 6, 2023

LECANEMAB APPROVAL

We are all ecstatic here at ARTC with the approval of the Lecanemab. This is the first disease modifying treatment to be approved anywhere in the world. This approval comes through the dedication and commitment of Eisai pharmaceutical company, as well as the many investigators and Subjects who participated in the various programs for this compound since 2013. ARTC has been at the forefront with this approval, leading the way as the Primary Investigative Site and treating more patients with this compound over the past decade than anyone else in the world! This is something we are extremely proud of and our direct contributions played a significant role with the approval of Lecanemab.

Over the course of this research hundreds of our patients have received immense benefit from participating. We want to extend a huge thank you to all our subjects and caregivers who have participated in not only this program but all of our programs to date. We, along with your help and commitment to clinical research, have changed the trajectory of this disease. With this approval we have started a new chapter in the fight against Alzheimer's disease. We know that this particular medication is not the sole answer for this devastating disease, and we will continue to fight each and every day by advancing compounds as rapidly as possible through clinical research until we've reached the ultimate goal of a cure and total eradication of Alzheimer's. This disease has destroyed so many lives and continues to humble us every single day. However, today is a day we celebrate and take our first breath of fresh air. As always, we want to acknowledge and thank everyone for their continued love, support, and prayers.

With heartfelt thanks and appreciation,

Dr. Watson and the entire ARTC Family